Prescription Drug News and Research

RSS

FDA accepts A.P. Pharma’s resubmission of NDA for APF530

A.P. Pharma, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of its New Drug Application (NDA) for APF530.

17 Oct 2012

Robert Wood Johnson Foundation announces winners of 2012 Community Health Leaders Award

The Robert Wood Johnson Foundation is proud to announce today the recipients of its 2012 Community Health Leaders Award, honoring 10 individuals who have surmounted significant challenges to help improve health and health care in their communities.

17 Oct 2012

First Edition: October 16, 2012

Today's early morning highlights from the major news organizations, including reports about a study regarding the possible impact of premium support on Medicare premiums.

16 Oct 2012

Higher health care premiums could wipe out social security increases; Medicare enrollment begins

Social Security recipients shouldn't expect a big increase in monthly benefits come January. Preliminary figures show the annual benefit boost will be between 1% and 2%, which would be among the lowest since automatic adjustments were adopted in 1975.

16 Oct 2012

More Medicare Advantage Plans get top ratings

Privately-run health insurance companies that contract with Medicare are scoring higher in a government-backed quality rating system designed to guide seniors to better medical care choices and service, the Obama administration announced Friday. The so-called "Medicare Advantage Plans" are performing better with more of them hitting four- and five-star ratings on the five-star scale, said U.S. Secretary for Health and Human Services Kathleen Sebelius and officials from the Centers for Medicare and Medicaid Services.

15 Oct 2012

Walmart, Humana to help Medicare beneficiaries afford their prescriptions

Annual enrollment begins today for 2013 Medicare plans and Humana Inc. and Walmart will once again help beneficiaries afford their prescriptions.

15 Oct 2012

Vice Presidential candidates debate Medicare plan specifics

During last night's face off, Vice President Joe Biden and GOP vice presidential hopeful Paul Ryan offered different plans, visions and, sometimes, even numbers for Medicare's future.

13 Oct 2012

Research roundup: Addressing disparities in cancer diagnosis time, Medicare open season awareness

Researchers tested the effectiveness of using patient navigation programs with women who have abnormal breast or cervical cancer screenings. These programs aim to facilitate treatment by such things as arranging financial support, transportation to appointments, child care or interpreter services.

13 Oct 2012

Cardioviva can help fill the gap between diet, exercise and drugs

Over half (52 percent) of supplement users are concerned about their heart health and 73 percent express an interest in natural, clinically proven solutions for cholesterol reduction, according to market research conducted by Micropharma Limited, a pioneer in the development of innovative and effective probiotics.

12 Oct 2012

Survey finds seniors satisfied with Medicare Part D

The national survey of 2,363 seniors, which was conducted by Medicare Today, found 90 percent are satisfied with their Medicare prescription drug coverage.

5 Oct 2012

Overweight children more likely to take prescription medications

Overweight children are far more likely to take prescription medications than children of a normal weight-a trend that adds to already higher health-care costs for treating childhood obesity, according to new research from the University of Alberta.

5 Oct 2012

A flood of post-debate fact checking follows points and counterpoints

News outlets examined a range of issues brought up during last night's presidential face-off, ranging from discussions of the $716 billion Medicare cut to talk of death panels and whether the health law promise of lower health insurance costs came true.

5 Oct 2012

New ToxIC study identifies current drug poisoning trends

Nonprescription medications are just as likely a cause of poisoning as prescription drugs, according to a new study by Timothy Wiegand, M.D. from the University of Rochester Medical Center in the US and colleagues.

5 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

Issa threatens to subpoena HHS documents related to Medicare Advantage bonuses

Rep. Darrell Issa, R-Calif., chairman of the House Oversight and Government Reform Committee, alleges that the Department of Health and Human Services is using an $8 billion Medicare bonus payment demonstration project to mask the health law's cuts to Medicare Advantage plans in advance of the election.

29 Sep 2012

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

29 Sep 2012

Extend Health announces availability of two free guides for seniors

Extend Health, operator of the nation's largest private Medicare exchange and a Towers Watson company, announced today the availability of two free guides designed to help seniors who are turning 65 - and becoming eligible for Medicare for the first time - navigate the complexity of their health care options to make informed choices about Medicare coverage.

28 Sep 2012

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

The U.S. Food and Drug Administration today approved Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).

28 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012